Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma

被引:50
作者
Cavo, M. [1 ]
Pantani, L. [1 ]
Pezzi, A. [1 ]
Petrucci, M. T. [2 ]
Patriarca, F. [3 ]
Di Raimondo, F. [4 ]
Marzocchi, G. [1 ]
Galli, M. [5 ]
Montefusco, V. [6 ]
Zamagni, E. [1 ]
Gamberi, B. [7 ]
Tacchetti, P. [1 ]
Brioli, A. [1 ]
Palumbo, A. [8 ]
Sonneveld, P. [9 ]
机构
[1] Univ Bologna, Sch Med, Seragnoli Inst Hematol, Bologna, Italy
[2] Univ Roma La Sapienza, Azienda Policlin Umberto 1, I-00185 Rome, Italy
[3] Hematol & Bone Marrow Transplant Unit, Udine, Italy
[4] Univ Catania, Dept Clin & Mol Biomed, Catania, Italy
[5] Papa Giovanni XXIII Hosp, Hematol, Bergamo, Italy
[6] Fdn IRCCS Ist Nazl Tumori, Hematol Bone Marrow Transplantat, Milan, Italy
[7] Arcispedale S Maria Nuova, Hematol, Reggio Emilia, Italy
[8] Univ Turin, AOU S Giovanni Battista Torino, Turin, Italy
[9] Erasmus MC, Dept Hematol, Rotterdam, Netherlands
关键词
RANDOMIZED PHASE-3; PLUS DEXAMETHASONE; TRIAL; CYBORD;
D O I
10.1038/leu.2015.274
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:2429 / 2431
页数:4
相关论文
共 15 条
[1]   CyBorD induction therapy in clinical practice [J].
Areethamsirikul, N. ;
Masih-Khan, E. ;
Chu, C-M ;
Jimenez-Zepeda, V. ;
Reece, D. E. ;
Trudel, S. ;
Kukreti, V. ;
Tiedemann, R. ;
Chen, C. .
BONE MARROW TRANSPLANTATION, 2015, 50 (03) :375-379
[2]   The impact of intra-clonal heterogeneity on the treatment of multiple myeloma [J].
Brioli, Annamaria ;
Melchor, Lorenzo ;
Cavo, Michele ;
Morgan, Gareth J. .
BRITISH JOURNAL OF HAEMATOLOGY, 2014, 165 (04) :441-454
[3]   International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation [J].
Cavo, Michele ;
Rajkumar, S. Vincent ;
Palumbo, Antonio ;
Moreau, Philippe ;
Orlowski, Robert ;
Blade, Joan ;
Sezer, Orhan ;
Ludwig, Heinz ;
Dimopoulos, Meletios A. ;
Attal, Michel ;
Sonneveld, Pieter ;
Boccadoro, Mario ;
Anderson, Kenneth C. ;
Richardson, Paul G. ;
Bensinger, William ;
Johnsen, Hans E. ;
Kroeger, Nicolaus ;
Gahrton, Gosta ;
Bergsagel, P. Leif ;
Vesole, David H. ;
Einsele, Hermann ;
Jagannath, Sundar ;
Niesvizky, Ruben ;
Durie, Brian G. M. ;
San Miguel, Jesus ;
Lonial, Sagar .
BLOOD, 2011, 117 (23) :6063-6073
[4]   Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study [J].
Cavo, Michele ;
Tacchetti, Paola ;
Patriarca, Francesca ;
Petrucci, Maria Teresa ;
Pantani, Lucia ;
Galli, Monica ;
Di Raimondo, Francesco ;
Crippa, Claudia ;
Zamagni, Elena ;
Palumbo, Antonio ;
Offidani, Massimo ;
Corradini, Paolo ;
Narni, Franco ;
Spadano, Antonio ;
Pescosta, Norbert ;
Deliliers, Giorgio Lambertenghi ;
Ledda, Antonio ;
Cellini, Claudia ;
Caravita, Tommaso ;
Tosi, Patrizia ;
Baccarani, Michele .
LANCET, 2010, 376 (9758) :2075-2085
[5]   International uniform response criteria for multiple myeloma [J].
Durie, B. G. M. ;
Harousseau, J-L ;
Miguel, J. S. ;
Blade, J. ;
Barlogie, B. ;
Anderson, K. ;
Gertz, M. ;
Dimopoulos, M. ;
Westin, J. ;
Sonneveld, P. ;
Ludwig, H. ;
Gahrton, G. ;
Beksac, M. ;
Crowley, J. ;
Belch, A. ;
Boccadaro, M. ;
Turesson, I. ;
Joshua, D. ;
Vesole, D. ;
Kyle, R. ;
Alexanian, R. ;
Tricot, G. ;
Attal, M. ;
Merlini, G. ;
Powles, R. ;
Richardson, P. ;
Shimizu, K. ;
Tosi, P. ;
Morgan, G. ;
Rajkumar, S. V. .
LEUKEMIA, 2006, 20 (09) :1467-1473
[6]   Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma [J].
Kumar, Shaji ;
Flinn, Ian ;
Richardson, Paul G. ;
Hari, Parameswaran ;
Callander, Natalie ;
Noga, Stephen J. ;
Stewart, A. Keith ;
Turturro, Francesco ;
Rifkin, Robert ;
Wolf, Jeffrey ;
Estevam, Jose ;
Mulligan, George ;
Shi, Hongliang ;
Webb, Iain J. ;
Rajkumar, S. Vincent .
BLOOD, 2012, 119 (19) :4375-4382
[7]   Bortezomib-Cyclophosphamide-Dexamethasone (VCD) versus Bortezomib-Thalidomide-Dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis [J].
Leiba, Merav ;
Kedmi, Meirav ;
Duek, Adrian ;
Freidman, Tzachi ;
Weiss, Mia ;
Leiba, Ronit ;
Nagler, Arnon ;
Avigdor, Abraham .
BRITISH JOURNAL OF HAEMATOLOGY, 2014, 166 (05) :702-710
[8]   Association of response endpoints with survival outcomes in multiple myeloma [J].
Lonial, S. ;
Anderson, K. C. .
LEUKEMIA, 2014, 28 (02) :258-268
[9]   Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma [J].
Mai, E. K. ;
Bertsch, U. ;
Duerig, J. ;
Kunz, C. ;
Haenel, M. ;
Blau, I. W. ;
Munder, M. ;
Jauch, A. ;
Schurich, B. ;
Hielscher, T. ;
Merz, M. ;
Huegle-Doerr, B. ;
Seckinger, A. ;
Hose, D. ;
Hillengass, J. ;
Raab, M. S. ;
Neben, K. ;
Lindemann, H-W ;
Zeis, M. ;
Gerecke, C. ;
Schmidt-Wolf, I. G. H. ;
Weisel, K. ;
Scheid, C. ;
Salwender, H. ;
Goldschmidt, H. .
LEUKEMIA, 2015, 29 (08) :1721-1729
[10]   Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma [J].
Moreau, Philippe ;
Avet-Loiseau, Herve ;
Facon, Thierry ;
Attal, Michel ;
Tiab, Mourad ;
Hulin, Cyrille ;
Doyen, Chantal ;
Garderet, Laurent ;
Randriamalala, Edouard ;
Araujo, Carla ;
Lepeu, Gerard ;
Marit, Gerald ;
Caillot, Denis ;
Escoffre, Martine ;
Lioure, Bruno ;
Benboubker, Lotfi ;
Pegourie, Brigitte ;
Kolb, Brigitte ;
Stoppa, Anne Marie ;
Fuzibet, Jean-Gabriel ;
Decaux, Olivier ;
Dib, Mamoun ;
Berthou, Christian ;
Chaleteix, Carine ;
Sebban, Catherine ;
Traulle, Catherine ;
Fontan, Jean ;
Wetterwald, Marc ;
Lenain, Pascal ;
Mathiot, Claire ;
Harousseau, Jean-Luc .
BLOOD, 2011, 118 (22) :5752-5758